Xiamen Amoytop Biotech Co., Ltd. Deal History & Licensing Activity
Xiamen Amoytop Biotech Co., Ltd. is a life sciences. Over the past three years, Xiamen Amoytop Biotech Co., Ltd. has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals). The company currently has 7 active clinical trials, primarily in Infectious Disease.
Deals (12mo)
2
Active Trials
7
Top Modality
Small Molecules
Focus Area
Infectious Disease
Xiamen Amoytop Biotech Co., Ltd. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Xiamen Amoytop Biotech Co., Ltd. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| pevifoscorvir sodium | Amoytop | Small Molecules | Phase 2 | license | Apr 2026 |
| pevifoscorvir sodium | Aligos Therapeutics, Inc. | Small Molecules | Phase 2 | license | Apr 2026 |
Xiamen Amoytop Biotech Co., Ltd. Pipeline Focus
Therapeutic areas and modalities where Xiamen Amoytop Biotech Co., Ltd. is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Xiamen Amoytop Biotech Co., Ltd. Strategic Signals
Key indicators of Xiamen Amoytop Biotech Co., Ltd.'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Xiamen Amoytop Biotech Co., Ltd. Clinical Pipeline
Xiamen Amoytop Biotech Co., Ltd. has 7 active clinical trials across 4 development phases.
2
Not Applicable
2
Phase 1
1
Phase 2
2
Phase 3
See How Your Asset Matches Xiamen Amoytop Biotech Co., Ltd.'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Xiamen Amoytop Biotech Co., Ltd. Licensing & Deal Activity
Xiamen Amoytop Biotech Co., Ltd. is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Xiamen Amoytop Biotech Co., Ltd. ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Xiamen Amoytop Biotech Co., Ltd. include Infectious Disease (4 deals and trials), Infectious (2 deals and trials), Autoimmune (1 deal and trial), and Hematological Malignancies (1 deal and trial). In terms of modality, Xiamen Amoytop Biotech Co., Ltd. has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Xiamen Amoytop Biotech Co., Ltd. and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Xiamen Amoytop Biotech Co., Ltd.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.